Jodon G, Colton MD, Cai AR, et al. - Despite drastic improved outcomes resulting from chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) lymphomas, a subset of patients will not respond to treatment or will relapse quickly post- an initial response, therefore, researchers undertook this single-center retrospective study to further reveal patient clinical and radiographic variables that could predict a response to CAR-T therapy. Participants were all R/R lymphoma patients who were administered infusion of CAR T-cells from 2017-2020 and underwent one PET scan post-treatment for response assessment. The median progression free survival and median overall survival were estimated to be 9.6 and 19.9 months, respectively. Findings revealed that R/R lymphoma patients who were at high risk for progression and/or poor overall survival following CAR T-cell therapy were identified by both clinical (advanced stage, elevated CRP and ferritin, CNS involvement) as well as radiographic variables [delta SUVmax(standardized uptake value)].